Skip to main content
Clinical Trials/EUCTR2005-005528-15-GB
EUCTR2005-005528-15-GBActive, not recruitingPhase 1

A RANDOMISED CONTROLLED TRIAL TO STUDY THE SIDE EFFECT PROFILE AND TO ESTABLISH MEASURES OF EFFICACY USING PHOTOFRIN OR 5 AMINOLAEVULINIC ACID PHOTODYNAMIC THERAPY IN THE ERADICATION OF DYSPLASIA IN BARRETT’S COLUMNAR LINED OESOPHAGUS - RCT of ALA and Photofrin PDT for HGD in Barrett's Oesophagus

niversity College London0 sites64 target enrollmentStarted: December 19, 2005Last updated:
Drugs

Trial Snapshot

Phase
Phase 1
Status
Active, not recruiting
Sponsor
Enrollment
64

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional clinical trial of medicinal product

Eligibility Criteria

Inclusion Criteria

  • 1.Patients will be recruited from those referred to the National Medical Laser Centre for management of HGD in BE.
  • 2.Patients with biopsy proven Barrett’s Columnar Lined Oesophagus and high-grade dysplasia confirmed by 2 independent pathologists, and no evidence of invasive cancer. Biopsies will be taken at surveillance endoscopy from each quadrant of the oesophagus every 2 cm through the length of the Barrett’s Oesophagus segment.
  • 3.Patients with a visible distinct nodule of HGD will be eligible for inclusion following endoscopic mucosal resection or other ablative therapy to this nodule provided residual HGD remains in the patient’s Barrett’s segment.
  • 4.Patients may have an endoscopic ultrasound to confirm non-invasive disease as clinically indicated.
  • 5.Patients to be double stratified into:
  • (a) Short or Long Segment BE: Short segment defined as 6 cm or less (single length treatment) and Long segment defined as >6cm but up to 13cm (double length treatment)
  • (b) Single or Multiple sites of high grade dysplasia.
  • 5The maximum length of Barrett’s oesophagus eligible for inclusion into the study will be 13cm.
  • 6Patients must have no contraindications to endoscopy.
  • 7Males and non-pregnant females over the age of 21 years. Female patients who are pre-menopausal must practice a medically acceptable form of contraception.
  • 8Patients must sign an informed consent form.
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range

Exclusion Criteria

  • 1Presence of invasive carcinoma of the oesophagus.
  • 2History of severe cardiovascular disease, severe angina, congestive heart failure, or recent syncope of cardiovascular origin.
  • 3Patients presenting with abnormal cardiac signs or symptoms and signs of congestive heart failure on physical examination.
  • 4Patients with orthostatic hypotension resistant to hydration.
  • 5Patients in whom endoscopy is contraindicated.
  • 6Patients who have a history of porphyria, or hypersensitivity to porphyrins.
  • 7Patients taking depot preparations of psychotropic medication
  • 8Patients with a WBC <2x109/L.
  • 9Patients with a platelet count <50x109/L.
  • 10Patients with a prothrombin time >1.5 times the upper limit of normal.
  • 11Patients with impaired renal and/or hepatic function at time of entry into the study (total serum bilirubin >50 mcmol/L, serum creatinine >200 mcmol/L, alkaline phosphatase (of hepatic origin) and/or ALT >2 times upper limit of normal).
  • 12Patients are not allowed to receive concurrent chemotherapy, or radiation therapy or chemotherapy within 4 weeks of entry into this study.
  • 13Patients with prior PDT for Barrett’s Columnar Lined Oesophagus.
  • 14Barrett’s Oesophagus greater than 13cm in length.

Investigators

Sponsor
niversity College London

Similar Trials